Pre-exposure prophylaxis in the perinatal period
Domaine:
healthcareType de record:
paper
Créateur:
SaiSch
Éditeur:
Hôte:
Women in sub-Saharan Africa are at high risk for HIV
acquisition during pregnancy and postpartum periods,
which puts the health of perinatal people at risk, but also
contributes to new paediatric infections. Pre-exposure
prophylaxis (PrEP) to prevent HIV is a highly effective
intervention to prevent HIV acquisition. Unfortunately,
limited inclusion of pregnant and postpartum women in
phase 3 clinical research studies typically results in a lag
of safety data for perinatal people and delayed approvals
of new products for this population. Despite years of
surveillance data among pregnant and postpartum
people living with HIV using emtricitabine and tenofovir
disoproxil fumarate for treatment, recommendations to
offer oral PrEP to pregnant and postpartum women were
only adopted in South Africa in 2021, slowing access and
implementation lessons.
Similaires
Youth perceptions of pre-exposure prophylaxis and post-exposure prophylaxis: The case of Ulundi Local Municipality in KwaZulu-NatalUnderstanding Pre-Exposure Prophylaxis Adherence in Young Women in KenyaAwareness, Availability and Accessibility of Pre-Exposure Prophylaxis (PREP) and Post Exposure Prophylaxis (PEP) in Health Institutions in Ekiti State, NigeriaCost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxisMobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in AfricaUsing developmental evaluation to implement an oral pre-exposure prophylaxis (PrEP) project in Kenya